Hypoxia-Specific Metal–Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound
ACS Nano · 16.07.2024 · 18 (28) · 18412-18424
DOI: 10.1021/acsnano.4c02921 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, online erschienen am 01.07.2024. Verfasst von Jingnan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, 400016 Chongqing, P.…. Hauptthemen laut MEDLINE: Metal-Organic Frameworks, Immunotherapy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Ultrasound in Medicine and Engineering, College of Biomedical Engineering, Chongqing Medical University, 400016 Chongqing, P. R. China.
ORCID-Profile: Huanan Li
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, J., Luo, C., Sun, T., Zhou, Y., Huang, X., Wu, D., Luo, X., Zeng, C., & Li, H. (2024). Hypoxia-Specific Metal–Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound. ACS Nano, 18(28), 18412-18424. https://doi.org/10.1021/acsnano.4c02921
Vancouver
Li J, Luo C, Sun T, Zhou Y, Huang X, Wu D, et al. Hypoxia-Specific Metal–Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound. ACS Nano. 2024;18(28):18412-18424. doi:10.1021/acsnano.4c02921
BibTeX
@article{Li2024,
author = {Li, Jingnan and Luo, Chengyan and Sun, Tingyu and Zhou, Yinglin and Huang, Xinchang and Wu, Dezhou and Luo, Xirui and Zeng, Chao and Li, Huanan},
title = {Hypoxia-Specific Metal–Organic Frameworks Augment Cancer Immunotherapy of High-Intensity Focused Ultrasound},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {28},
pages = {18412--18424},
doi = {10.1021/acsnano.4c02921}
}
EUVIMED